Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPAFOX: FOLFIRINOX vs Gemcitabine in Resectable Pancreatic Cancer
NCT02172976Phase 3Completed
- Sponsor
- Krankenhaus Nordwest
- Start
- Nov 2014
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, irinotecan, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Krankenhaus Nordwest. Primary endpoint: Overall Survival at 24 months. Started Nov 2014; status: completed.
02
Drugs
oxaliplatinirinotecanfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02172976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172976.